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Prostatic bud formation
Mouseatic budding patterns occurs early in prostate development but mechanisms
responsible for this event are poorly understood. We investigated the role of WNT5A in patterning prostatic
buds as they emerge from the fetal mouse urogenital sinus (UGS). Wnt5a mRNA was expressed in UGS
mesenchyme during budding and was focally up-regulated as buds emerged from the anterior, dorsolateral,
and ventral UGS regions. We observed abnormal UGS morphology and prostatic bud patterns in Wnt5a null
male fetuses, demonstrated that prostatic bud number was decreased by recombinant mouse WNT5A
protein during wild type UGS morphogenesis in vitro, and showed that ventral prostate development was
selectively impaired when these WNT5A-treated UGSs were grafted under under kidney capsules of
immunodeﬁcient mice and grown for 28 d. Moreover, a WNT5A inhibitory antibody, added to UGS organ
culture media, rescued prostatic budding from inhibition by a ventral prostatic bud inhibitor, 2,3,8,7-
tetrachlorodibenzo-p-dioxin, and restored ventral prostate morphogenesis when these tissues were grafted
under immunodeﬁcient mouse kidney capsules and grown for 28 d. These results suggest that WNT5A
participates in prostatic bud patterning by restricting mouse ventral prostate development.
© 2008 Elsevier Inc. All rights reserved.Introduction
The mature mouse prostate is comprised of four bilaterally
symmetric lobes: anterior, dorsal, lateral and ventral. Each prostate
lobe features unique ductal morphology and gene expression proﬁles,
yet they all arise from a common primordium, the urogenital sinus
(UGS). Speciﬁcation of prostate lobar identity begins during embry-
ogenesis and is mediated by androgen-dependent interactions
between UGS mesenchyme (UGM), and UGS epithelium, UGE
(Cunha et al., 1987). These interactions promote outgrowth of ductal
precursors, or buds, that derive from UGE in a distinct spatial pattern
and temporal sequence (Lin et al., 2001). Buds on the anterior UGE
surface emerge ﬁrst, as early as embryonic day (E) 16.5, and give rise to
anterior prostate ducts. Dorsal prostate buds also emerge on E16.5 and
lateral and ventral buds are the last to appear on approximately E17.5.
Budding is a recurrent theme in limb, lung, tooth, and feather
development (Hogan, 1999). While morphogenetic signals often
overlap in these tissues, prostate induction is distinguished by its
androgen-dependence. Androgen receptors (ARs) in UGM are neces-
sary for bud initiation and UGM is also largely responsible forharmacy, 777 Highland Ave.,
. Peterson).
l rights reserved.specifying bud patterns (Cunha and Chung, 1981; Cunha and Lung,
1978; Goldstein and Wilson, 1975).
Themost fundamental aspect of the prostatic buddingmechanism,
how activation of ARs by fetal testosterone participates in bud
initiation and patterning, remains unknown. This issue is being
addressed by complementary approaches. The ﬁrst, a chemical
genetics approach, uses chemical inhibitors of prostatic budding
that act in a region-selective fashion. This approach has revealed some
molecular signals involved in prostatic bud patterning. Estrogen
receptors were implicated in dorsolateral prostatic budding when it
was discovered that estrogen receptor agonists, diethylstilbesterol and
bisphenol A, inhibited dorsolateral bud formation (Timms et al., 2005).
The nuclear orphan receptor, aryl hydrocarbon receptor (AHR), was
implicated in ventral prostatic budding after it was discovered that
ventral buds were selectively impaired by the AHR agonist, 2,3,7,8-
tetrachlorodibenzo-p-dioxin, TCDD (Lin et al., 2003).
The use of transgenic mice and in vitro models of prostate growth
have also elucidated signaling factors participating in prostate
induction and patterning. ARs are required for prostate budding in
all UGS zones (Lasnitzki and Mizuno, 1980); ﬁbroblast growth factor
10 (Fgf10) is required for the formation of most buds (Donjacour et al.,
2003); Noggin is required for ventral and anterior prostatic buds (Cook
et al., 2007); Sry box 9 (Sox9) is required for ventral buds and likely
also for other buds (Thomsen et al., 2008), homeobox (Hox) a13 and
d13 are involved in budding in all zones (Podlasek et al., 1999b) but
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1997). Also involved in prostatic budding are sonic hedgehog (SHH)
and retinoic acid, which are prostatic bud agonists and bone
morphogenetic proteins (BMPs) 4 and 7, which are prostatic bud
antagonists (Doles et al., 2006; Grishina et al., 2005; Lamm et al.,
2002; Podlasek et al., 1999a; Vezina et al., 2008). It is unclear at this
time how AR, FGF, SHH, BMP, and HOX signals are orchestrated to
initiate buds and establish prostatic bud patterns. None of these
signals can account completely for the generation of prostatic bud
patterns, suggesting that additional factors or coordinated interac-
tions of multiple signals are involved.
Genes of the wingless-related MMTV integration site (Wnt)
superfamily have been associated with bud initiation and patterning
in multiple tissues (Gat et al., 1998; Liu et al., 2008; Liu et al., 2007; Lu
et al., 2004; Noramly et al., 1999; Teuliere et al., 2005; Widelitz et al.,
2000). WNTs are embedded in a molecular signaling pathway that
interfaces with FGF, SHH, BMP, and HOX signaling. Further, Wnts are
also expressed in the UGS during prostatic budding (Joesting et al.,
2008; Zhang et al., 2006), but their role in prostatic bud initiation had
not been investigated.
Secreted Wnts bind to receptors on target tissues and initiate
signaling through two principle mechanisms: a canonical signaling
pathway involving stabilization of β-catenin, and a less understood
non-canonical, β-catenin-independent signaling pathway.Wnt5a, the
most abundantly expressed Wnt gene in the UGS (Zhang et al., 2006),
signals through the non-canonical pathway and its deletion has been
shown to impede budding in other developing mouse tissues
(Yamaguchi et al., 1999).
In the present study, we sought to determine whether Wnt5a is
involved in prostatic bud initiation and patterning in the male fetal
mouse UGS. We characterized Wnt5a mRNA expression in the UGS,
assessed development of the UGS and related structures in theWnt5a
null fetus, and evaluated the effects of exogenous WNT5A protein and
WNT5A inhibitory antibody on prostatic bud formation and pattern-
ing in UGS organ culture. The signiﬁcance of our ﬁndings is that they
reveal for the ﬁrst time that WNT5A signaling participates in prostatic
bud patterning by restricting ventral prostatic bud formation during
prostate morphogenesis.
Materials and methods
Animals
Wnt5a null mice, backcrossed onto a C57BL/6 background
(Yamaguchi et al., 1999), were obtained from Terry Yamaguchi (NCI,
Frederick, MD). Offspring were genotyped as previously described
(Benedict et al., 2000) using the following primers to identify
heterozygous breeders: mouse WNT5A primer 5′-TTCCAAGTTCTTCC-
TAATGGC-3′ and E. coli neomycin resistance cassette primer 5′-
TTGGGTGGAGAGGCTATTCG-3′. C57BL/6J wild-type mice were from
the Jackson Laboratory (Bar Harbor, ME). Animals were housed with a
12 h light–dark cycle (lighted 0600 to 1800 h) at room temperature
(22±1 °C) in clear plastic microisolator cages with corn-cob bedding.
Feed (5015 Mouse Diet, PMI Nutrition International, Brentwood, MO)
and water were available ad libitum.
Timed-pregnant females were generated by housing males and
females together overnight. The day after overnight mating was
designated E0.5. Pregnant damswere treated as described below, then
euthanized by CO2 overdose prior to removal of fetuses. UGS samples
in each experimental block were taken from separate litters to
minimize litter-dependent observations. Some pregnant dams were
exposed to the ventral prostatic budding inhibitor TCDD (5 μg/kg, po).
Dosing occurred on either E13.5 or E15.5, either of which has been
shown previously to inhibit ventral bud formation (Vezina et al., in
press). All procedures were approved by the University of Wisconsin
Institutional Animal Care and Use Committee.Vibratome sectioning and sectional in situ hybridization
UGSs were ﬁxed overnight in 4% paraformaldehyde, dehydrated in
methanol, rehydrated in phosphate-buffered saline containing 0.1%
Tween-20 (PBT), embedded in 4% SeaPlaque agarose in PBT (Biowhit-
taker Molecular Applications, Rockland, ME), and cut into 80 μm
sections using a double-edged razormounted on a vibratome emersed
in PBT. In situ hybridization was performed on UGS sections as
described by Vezina et al. (in press). The Wnt5a riboprobe was a gift
from Dr. Terry Yamaguchi (NCI, Frederick, MD).
Scanning electron microscopy and bud counting
UGS samples were prepared for scanning electron microscopy
(SEM) as previously described (Lin et al., 2003). For experiments
involving bud counting, at least four views of each UGS were obtained
such that all surfaces of the UGS could be viewed. Two reviewers
independently counted the total number of buds for each UGS and
these counts were averaged to give the best estimate of actual bud
number for each. At least ﬁve UGSs were examined in this manner for
each treatment group.
Testicular testosterone content
Testicular testosterone content was measured with the Correlate-
EIA Testosterone Enzyme Immunoassay Kit (Assay Designs, Inc., Ann
Arbor, MI). Steroids were extracted from E18.5 fetal testes with ethyl
acetate, extracts were dried and reconstituted in manufacturer
supplied buffer, and testicular content was measured according to
the manufacturer’s instructions. Results are presented as the mean±
SEM for 7 litter-independent males of each genotype.
UGS organ culture
E14.5 UGSs were collected and cultured as described previously
(Vezina et al., 2008). Cultured UGSs were exposed to 10 nM 5α-
dihydrotestosterone (DHT, Sigma) and either dimethyl sulfoxide
(DMSO, 0.1% v/v) or 1 nM TCDD dissolved in 0.1% DMSO. Some
cultures were also exposed to graded concentrations of recombinant
mouse WNT5A protein (rmWNT5A [80% purity], 0.5, 1, or 2 μg/ml; R
and D Systems, Minneapolis, MN), goat anti-mouseWNT5A inhibitory
antibody (anti-WNT5A-IgG, 4 or 8 μg/ml; R and D Systems), or
rmWNT5A (2 μg/ml)+ anti-WNT5A-IgG (8 μg/ml). Anti-WNT5A-IgG
was certiﬁed to exhibit less than 2% cross-reactivity with WNT4 and
WNT10b by the manufacturer. Media and treatments were replaced
every 48 h.
Renal grafting
E14.5 UGSs cultured for 3 d as described above, or E18.5 UGSs
removed from WT male and Wnt5a null male fetuses were grafted
under the renal capsules of adult male nu/nu immunodeﬁcient mice
(Harlan, Indianapolis, IN). Mice received oral antibiotics (Sulfatrim
Suspension, Alpharma, Fort Lee, NJ) for one week following surgery.
Grafts were removed after 28 d and either ﬁxed with formalin,
dehydrated in ethanol, and embedded in parafﬁn for histology or
frozen in liquid nitrogen and stored at −80°C for RT-PCR.
Calcium imaging
To assess rmWNT5A and anti-WNT5A-IgG activity, mouse embryo-
nic ﬁbroblasts (MEFs) were obtained from American Tissue Type
Culture Collection (Manassas, VA). MEFs were seeded on 35mm tissue
culture dishes 24 h prior to measurement of intracellular free calcium.
MEFs were cultured in Dulbecco’s Minimal Essential Medium
supplemented with 10% heat-inactivated fetal bovine serum, and
Fig. 1.Wnt5a transcripts are expressed in male mouse UGS mesenchyme (UGM) during prostatic bud formation and are increased focally where buds emerge from each UGS zone.
Wnt5amRNA distributionwas determined by in-situ hybridization (ISH) of mid-sagittal male UGS tissue sections at E15.5,16.5, and 17.5. Results are representative of three UGSs from
each day. Colored dashed lines demarcate the UGE-UGM interface in the anterior (red), dorsolateral (green), and ventral (yellow) prostatic budding zones, respectively. Wnt5a-
positive staining is dark blue.
Table 1
Incidence of urogenital defects in E18.5 Wnt5a null male fetuses
Type of defecta Wnt5a null fetuses # affected/# observed
Undescended testes 14/14
Bladder agenesis 4/14
UGS agenesis 4/14
Pelvic urethra agenesis 9/14
Hindgut-UGS ﬁstulab 10/10
a None of these defects were observed in wild type littermates (nN14).
b Results reported only for Wnt5a null fetuses in which the UGS had formed.
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incubator. MEFs were incubated for 1 h with 10 μM Calcium Green-1
AM (Molecular Probes, OR), washed with culture medium to remove
unincorporated dye, and then maintained in 2 ml culture media for
confocal ﬂuorescent microscopy as described previously (Verbny et al.,
2002). A 500× stock solution of rmWNT5A and anti-WNT5A-IgG were
prepared in Hank’s balanced Salt Solution (HBSS) and diluted intoMEF
culture media.
Real-time reverse-transcription PCR
Real-time reverse transcription polymerase chain reaction was
performed as previously described (Lin et al., 2002). Primer sequences,
annealing temperatures, and product sizes are provided in Supple-
mental Table 1.
Statistical analyses
Statistical analyses were performed using Statistica Software
(StatSoft, Inc., Tulsa, OK). Levene’s test was used to determine
homogeneity of variances between or among groups with equal n
values and the Brown–Forsythe test was used for groups with unequal
n values. Student's t-test was used to identify differences between
groups and one-way Analysis of Variance (ANOVA) to detect
differences among groups. Fisher’s Least Signiﬁcant Test was used
for multiple comparisons. A difference of pb0.05 was considered
signiﬁcant. Variances in mean bud number were not equal for all
treatment groups (Levene's test pb0.05), so differences in bud number
between groups were assessed using the nonparametric Mann–
Whitney U test.
Results
Wnt5a is expressed in UGS mesenchyme during prostatic bud formation
Wnt5a is themost abundantWnt transcript in themalemouse UGS
during prostatic budding (Zhang et al., 2006) but its spatial
distribution in the UGS has not been previously reported. We used
ISH to investigate Wnt5a mRNA expression at 24 h intervals prior to
and during prostatic budding (E15.5–17.5). Prior to bud initiation
(E15.5), Wnt5awas detected in a diffuse band of UGM circumscribingeach of the UGE zones from which prostatic buds emerge (Fig. 1). For
each embryonic day examined, Wnt5a was most abundant in UGS
zones where buds were forming and least abundant in non-budding
regions of the UGS.Wnt5awasmost abundant in the anterior budding
zone immediately after anterior bud formation (E16.5), was moder-
ately expressed in the dorsolateral prostatic budding zone during
dorsolateral bud initiation, andwas weakly expressed where buds had
not yet emerged in the ventral budding zone at E16.5.Wnt5a staining
on E17.5 appeared to be expressed at a much lower level in the ventral
UGS region during ventral budding compared to that observed during
budding from anterior and dorsolateral UGS regions. Wnt5a was also
observed in UGM juxtaposed to elongating anterior and dorsal
prostatic buds at E17.5, where expression was most robust at the
base of buds and dissipated towards bud tips.
Wnt5a-null mice exhibit multiple urogenital abnormalities
The presence of Wnt5a transcripts in areas where anterior and
dorsolateral prostatic buds were forming suggested it may be required
for budding. To test this hypothesis, prostatic budding was assessed in
wild-type (WT) and Wnt5a null mice at E18.5. Multiple urogenital
abnormalities were associated with the Wnt5a null phenotype,
including UGS agenesis in some fetuses. The incidence of speciﬁc
defects is reported in Table 1. The UGS and bladder were absent and
the hindgut ended blindly in approximately 30% of Wnt5a null male
fetuses (results not shown). In the 70% of Wnt5a null male fetuses
where the UGS was present, it was morphologically deformed, devoid
of a pelvic urethra, and attached by a ﬁstulous connection to the
hindgut (Fig. 1, arrowheads).
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fully-developed UGSs from Wnt5a null males. First, intact UGSs of
representative WT and E18.5 Wnt5a null male fetuses were photo-
graphed (Figs. 2A and C); second, amid-sagittal UGS section from each
genotypewas examined histologically (Figs. 2B and D); and third, after
the UGS was treated with trypsin and UGM was removed with ﬁne
forceps, the underlying UGE surface was examined by SEM and color
coded to reveal anterior (red), dorsolateral (green) and ventral
(yellow) prostatic buds (Fig. 3). The bladder neck and the prostatic
urethra containing the anterior and ventral prostatic budding zones
were truncated and widened in manyWnt5a null UGSs (Fig. 3).Wnt5a
null UGSs exhibited prostatic bud patterning defects associated with
this UGS deformity. Anterior buds were absent from all male Wnt5a
null UGSs, ventral buds were rarely observed and dorsolateral bud
number varied substantially between fetuses, but was always less
than WT (Fig. 3).
Abnormal testicular development in Wnt5a null fetuses could
impair prostatic budding by reducing circulating fetal testosterone. All
fourteen Wnt5a null male fetuses examined exhibited defects in
testicular descent. We therefore compared testicular testosterone
content in WT and Wnt5a null fetuses to investigate testicularFig. 2. E18.5Wnt5a null male fetuses exhibit aberrant hindgut and urogenital morphology. Im
for representative wild-type andWnt5a null male mouse fetuses. Results are representative o
lines. The E18.5 Wnt5a null UGSs shown in panels C and D feature a ﬁstulous hindgut (HG)
anatomy of wild-type UGSs in panels A and B. The other structure shown is bladder (BL).function in Wnt5a null fetuses. Loss of Wnt5a was associated with a
signiﬁcant reduction in fetal testicular testosterone (219±29 pg
testosterone/testis in Wnt5a null fetuses vs. 732±116 pg testoster-
one/testis in WT fetuses, pb0.05).
WNT5A is not required for bud formation and exogenous WNT5A inhibits
ventral budding
The Wnt5a null phenotype revealed a role for Wnt5a in the early
phase of UGS morphogenesis and in UGS-hindgut separation.
However, it was not possible to determine whether WNT5A was also
required for prostatic budding or if prostatic budding defects inWnt5a
null fetuses occurred secondary to pre-existing UGS deformities and
decreased testicular testosterone.
To determine if WNT5A signaling is directly required for prostatic
bud formation, we assessed prostatic budding in a well-established, in
vitro serum-free UGS organ culture model, where bladder neck and
prostatic urethra morphology were normal at the start of the culture
period and androgen concentration in the culture medium was
sustained in the physiological range. Prostatic buds did not form in the
absence of androgens (results not shown) and all subsequentages of whole UGSs and hematoxylin and eosin stained sagittal UGS sections are shown
f ten fetuses from each genotype. Distal UGS boundaries are indicated by dashed white
-UGS connection (arrowhead) and agenic pelvic urethra (PU), compared to the normal
Fig. 4. Recombinant mouse WNT5A (rmWNT5A) restricts prostatic budding in mouse
UGS organ culture. E14.5 UGSs were cultured for 3 d in serum-free media containing
either 10 nM DHT and 0.1% DMSO (vehicle control, open bar) or DHT and graded
concentrations of rmWNT5A (solid bars). Prostatic bud number (all lobes) was
determined after the 3 d culture period by collecting each UGS, removing UGM as
described previously, and then imaging the underlying UGE by scanning electron
microscopy (SEM). A representative micrograph of a cultured UGS, after the
mesenchyme was removed to reveal the underlying prostatic buds, is shown for each
group. Prostatic buds are pseudocolored yellow. Results are mean±SEM of ﬁve UGSs per
group. Differences between groups were determined by ANOVA followed by Fisher's
least-signiﬁcant difference test. “⁎” indicates signiﬁcantly different from the vehicle
control (0 μg/ml rmWNT5A), pb0.05.
Fig. 3. E18.5 Wnt5a null male fetuses exhibit an aberrant prostatic bud pattern. UGS mesenchyme was removed from wild type and Wnt5a null UGSs and the underlying UGS
epithelium (UGE) was visualized by scanning electron microscopy. Results are representative of three UGSs per genotype. The Wnt5a null UGE shown above exhibits a shortened
and distended bladder neck (BN), is devoid of anterior (red) and ventral (yellow) prostatic buds, and exhibits fewer dorsolateral buds (green). Also evident is a ﬁstulous
connection (arrowhead) between UGS and hindgut (HG). HG is distinguished from seminal vesicle (SV) by its numerous epithelial protrusions. The other structure shown is the
pelvic urethra (PU).
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5α-dihydrotestosterone (DHT, an AR agonist). WNT5A signaling inWT
UGSs was then repressed by adding a WNT5A inhibitory antibody
(anti-WNT5A-IgG) to the culture medium or was activated by adding
recombinant mouse WNT5A (rmWNT5A) protein. These reagents
were used previously to repress or activate WNT5A signaling in
other systems (Castelo-Branco et al., 2006; Cheng et al., 2008;
Dejmek et al., 2006; Murdoch et al., 2003; Roarty and Serra, 2007;
Schulte et al., 2005). Their activities were conﬁrmed in this study
by measuring intracellular calcium mobilization (Supplemental Fig.
1) as a WNT5A-responsive endpoint (Ma and Wang, 2006;
Schleiffarth et al., 2007).
We next incubated WT UGSs in organ culture media containing 10
nM DHT and vehicle or anti-WNT5A-IgG (4 and 8 μg/ml) to determine
if WNT5A signaling was necessary for prostatic bud formation.
Prostatic budding was assessed by removing UGM, imaging under-
lying UGE from multiple angles by SEM, and enumerating the total
number of prostatic buds per UGS. Exposure to anti-WNT5A-IgG did
not change the number of prostatic buds formed in culture (results not
shown). This ﬁnding supports the hypothesis that WNT5A signaling is
not required for prostatic bud formation.
Functional redundancy has been observed for some mediators of
prostatic budding. For example, prostatic budding requires hedgehog
signaling but occurs normally in Shh null mice because indian
hedgehog is upregulated to compensate for loss of Shh (Doles et al.,
2006). An analogous mechanism may also trigger the upregulation of
a compensatory signal during in vitro incubation of UGSs with media
containing anti-WNT5A-IgG, and this may explain why prostatic bud
number was unchanged by treatment with anti-WNT5A-IgG. There-
fore, as an alternative approach to interrogate the role of WNT5A in
prostatic budding, we next investigated whether excess WNT5A
signaling impaired prostatic bud formation. UGSs were cultured for 3
d with media containing 10 nM DHT and graded concentrations of
exogenous rmWNT5A (0–2 μg/ml). Mean prostatic bud number was
signiﬁcantly reduced by rmWNT5A (1 and 2 μg/ml), to approximately
75% of the control value (Fig. 4). Inhibition of budding by rmWNT5A
appeared to be AR independent since it did not signiﬁcantly change Ar
mRNA abundance or abundance of the androgen-responsive gene
steroid 5 alpha-reductase 2 (results not shown).
ExcessWNT5A signaling blocked the formation of some, but not all
prostatic buds and we next investigated the hypothesis that WNT5A
selectively blocked development of certain prostate buds and not
others. UGSs were cultured for 3 d in the presence of vehicle (control)or an effective prostatic bud inhibitory concentration of rmWNT5A.
UGSs were then grafted under the kidney capsules of adult male
immunodeﬁcient mice and allowed to grow for 28 d. Prostate lobar-
development was assessed by histological examination and gene
expression proﬁling. Relative mRNA abundance of prostate lobe-
selective gene products was assessed by real-time RT-PCR. It was
established previously that probasin (Pbsn) is selectively expressed in
dorsal prostate, beta-microseminoprotein (Msmb) is selectively
expressed in lateral prostate, renin 1 (Ren1) is selectively expressed
in anterior prostate, and spermine binding protein (Sbp) is selectively
expressed in ventral prostate (Cook et al., 2007; Fabian et al., 1993;
Fujimoto et al., 2006; Kwong et al., 1999; Mills et al., 1987; Shi et al.,
2007; Thielen et al., 2007; Xuan et al., 1999). Arborization of prostate
ducts and cytodifferentiation of secretory luminal cells occurred
Fig. 5. Recombinant mouse WNT5A restricts ventral prostate development. E14.5 male
UGSs were cultured for 3 d with 10 nM DHT, 0.1% DMSO and either no rmWNT5A
(control, open bar) or 2 μg/ml rmWNT5A (solid bar) then grafted under the kidney
capsule of adult male nu/nu mice and grown for 28 d. Real-time RT-PCR was used to
measure abundance of a gene selectively expressed in ventral prostate, spermine
binding protein (Sbp), as an index of ventral prostate development. The abundance of
Sbp mRNA was normalized to peptidylprolyl isomerase A abundance, and results are
presented as mean±SEM of ﬁve grafted UGSs per in vitro treatment. Differences
between groups were determined by Student's t test. “⁎” indicates signiﬁcantly
different from vehicle control.
Fig. 6. A WNT5A inhibitory antibody (anti-WNT5A-IgG) counteracts the effects of a
selective ventral prostate inhibitor, TCDD, during mouse UGS development in vitro.
E14.5 UGSs were cultured for 3 d in serum-free media containing 10 nM DHT and 0.1%
DMSO (vehicle control, open bar) or these same two constituents and either TCDD (1
nM, gray-shaded bar) or TCDD+ anti-WNT5A-IgG (gray-shaded, diagonally slashed bar).
(A) Some cultured UGSs were imaged by scanning electron microscopy to assess total
bud count. (B) Other cultured UGSs were grafted under the kidney capsule of nu/nu
mice and grown for 28 d. Ventral prostate development was assessed by using real-
time, RT-PCR to measure abundance of the ventral prostate-selective transcript,
spermine binding protein (Sbp), in grafted tissues. Sbp abundance was normalized to
peptidylprolyl isomerase A. Results are mean±SEM of ﬁve UGS per treatment group.
Differences between groups were determined by ANOVA followed by Fisher’s least
signiﬁcant difference test. The presence of “⁎” indicates signiﬁcantly different from
vehicle control and “‡” indicates signiﬁcantly different from TCDD (pb0.05).
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rmWNT5A treatment group were devoid of ventral prostate ducts
(results not shown) and exhibited signiﬁcantly less Sbp (Fig. 5),
despite the presence dorsolateral and anterior prostate ducts and
normal levels of Pbsn, Msmb, and Ren1 (results not shown).
Antagonism of WNT5A signaling reverses ventral prostate inhibition
by TCDD
To independently conﬁrm that WNT5A acts selectively to block
development of ventral prostate, but not other lobes, we investigated
the effect of anti-WNT5A-IgG in a chemical model of ventral prostatic
budding inhibition. We demonstrated previously that ventral pro-
static budding was selectively impaired by TCDD, an agonist of the
AHR nuclear orphan receptor and transcription factor (Lin et al., 2003).
Since TCDD inhibits budding in a ventral UGS-selective fashion, we
hypothesized that inhibition of WNT5A signaling may rescue ventral
prostatic budding from inhibition by TCDD. UGSs were incubated for 3
d in organ culture media containing DHT and vehicle (control), TCDD,
or TCDD+ anti-WNT5A-IgG. TCDD alone signiﬁcantly reduced total
prostatic bud number and this effect was blocked by anti-WNT5A-IgG
(Fig. 5A). To test whether this restoration of bud number by anti-
WNT5A-IgG was due to the rescue of ventral bud formation, UGSs
from the treatment groups described above were grafted under the
kidney capsule of immunodeﬁcient mice and evaluated 28 d later.
Based on histological assessment and expression of transcripts that
are selectively expressed in each of the mouse prostate lobes, TCDD
did not impair development of anterior or dorsolateral prostate
(results not shown). The antibody alone did not signiﬁcantly change
prostatic bud number or impair development of anterior, dorsolateral,
or ventral prostate (results not shown). However, TCDD selectively
impaired development of ventral prostate and this was restored by
inhibition of WNT5A signaling with anti-WNT5A-IgG (Fig. 6). Thus,
inhibition of WNT5A signaling reverses the inhibitory actions of TCDD
on ventral prostatic budding.
Discussion
WNT5A is required for early events in urogenital development
This is the ﬁrst report, to our knowledge, that WNT5A is required
early in testes, bladder, pelvic urethra, and UGS formation.Wnt5a null
male mouse fetuses exhibited less testicular testosterone and thirty
percent did not form bladder or pelvic urethra. Of the 70% of Wnt5a
null male fetuses that formed bladder and UGS, only half formedpelvic urethra. It is worthwhile to note that agenesis of bladder, pelvic
urethra, and UGS was not gender-dependent and occurred at the
same frequency in male and female Wnt5a null mice (unpublished
observation).
Prostatic buddingwas impaired inWnt5a null malemice. However,
we were unable to replicate this aberrant budding phenotype by
pharmacologically inhibitingWNT5A signaling inWTUGSs cultured in
media containing anti-WNT5A-IgG. Our interpretation of these results
is thatWnt5amay contribute to, but alone is not required for prostatic
bud patterning. Instead, Wnt5a may be required for normal UGS
morphogenesis prior to budding. We suggest that truncation and
distention of anterior and ventral prostatic budding zones in Wnt5a
null males and decreased testosterone production predisposed these
mice to bud patterning defects that do not occur in morphologically
normal,WTUGSs. Itwas shown long ago that ventral prostatic buds are
the most sensitive to androgen. Ventral prostatic buds form in female
UGSs (Raynaud, 1942) even though circulating androgens are lower
than inmales (vom Saal,1989). Androgens induce prostatic budding in
female rats, with ventral prostatic bud formation occurring at lower
androgen doses compared to dorsolateral and anterior buds (Greene et
al., 1939). Therefore, absence of ventral buds in Wnt5a null UGSs
suggests that other factors, in addition to reduced testosterone levels in
these fetuses, contribute to ventral bud agenesis in these mice.
Excess Wnt5a negatively regulates ventral prostate development
Mechanisms responsible for prostatic bud patterning are poorly
understood. The signiﬁcance of our work is that it is the ﬁrst to report
impairment of ventral prostatic bud speciﬁcation by WNT5A, the
16 S.H. Allgeier et al. / Developmental Biology 324 (2008) 10–17prototypical non-canonical WNT protein. Effects of WNT5A on
prostatic budding are strikingly similar to those produced by TCDD,
a previously identiﬁed chemical inhibitor of ventral prostatic budding
and potent ligand of the AHR. We showed previously that AHR
signaling was not required for prostatic bud formation (Lin et al.,
2003) and showed in this study that WNT5A signaling also was not
required for prostatic budding in vitro. However, activation of either
AHR or WNT5A signaling inhibited budding. Addition of rmWNT5A or
TCDD to UGS organ culture meida blocked ventral prostate develop-
ment, as assessed by Sbp abundance and ventral prostate duct
formation in grafted tissues. The blockade of prostate development
by rmWNT5A and TCDD was ventral prostate-selective and did not
appreciably affect dorsolateral or anterior prostate development.
Inhibition of WNT5A signaling during UGS organ culture with TCDD
completely prevented the loss of buds associated with TCDD exposure
and permitted ventral prostate development. Collectively, these
results support our hypothesis that WNT5A is a ventral UGS region-
selective inhibitor of ventral prostate development in mice.
SOX9 was recently identiﬁed as a prostatic bud inhibitor (Thomsen
et al., 2008). Conditional deletion of Sox9 in cells that express the early
prostate marker NKX3.1 prevented ventral prostatic buds from
forming while having considerably lesser effects on prostatic budding
in other UGS regions. Since mesenchymal–epithelial interactions are
required for prostatic budding (Cunha and Chung, 1981) andWnt5a is
synthesized in UGS mesenchyme, SOX9 activity in UGS epithelium
may be mechanistically linked and downstream of WNT5A signaling
during prostatic bud formation.
Wnt5a overlaps Ar, Bmp4, and Hoxa13 during prostate speciﬁcation
Formation of bladder and UGS are supported by hormonally-
independent developmental pathways but prostatic bud patterning
and initiation require androgen (Lasnitzki and Mizuno, 1980). ARs in
UGM bind testosterone but in UGE do not (Takeda and Chang, 1991).
Activation of ARs in the periprostatic portion of UGM is particularly
important for prostate speciﬁcation (Takeda et al., 1987). Wnt5a
abundance was not directly regulated by androgens (results not
shown) but did overlap the purported location of AR activity. We
detected Wnt5a in periprostatic UGM prior to and during bud
formation. In UGS organ culture, rmWNT5A inhibited prostatic
budding without changing abundance of Ar mRNA or abundance of
Srd5a2, a gene that is directly regulated by activated AR. Thus,
inhibition of prostatic budding by exogenous WNT5A likely occurred
downstream of AR signaling.
Wnt5a is not required for prostatic budding in vivo. However,
Wnt5amRNA is up-regulated in anterior, dorsolateral, and ventral UGS
budding zones during bud formation in these regions. Coupled with
the fact that exogenous rmWNT5A inhibits prostatic budding, the
functional role of WNT5A during prostatic budding in vivo may be to
act in concert with other factors to limit the total number of buds that
form in each UGS zone, especially the ventral budding zone. A similar
role has been ascribed to Bmp4, which is also expressed in UGM
during budding and inhibits prostatic budding from cultured UGSs
(Lamm et al., 2001; Vezina et al., 2008). In future studies, we will
investigate interaction between Wnt5a and Bmp4 during prostatic
budding, since these factors appear to be involved in a signaling loop
in other tissues:Wnt5a is required for Bmp4 expression in developing
mouse lung (Li et al., 2002) and Bmp4 is required forWnt5a expression
in the genital tubercle (Oishi et al., 2003).
Hoxa13, which is required at least in part for normal prostatic bud
patterning (Warot et al., 1997), appears to functionally overlap Wnt5a
during uterine development (Mericskay et al., 2004) and has recently
been shown to controlWnt5a expression in mouse dermal ﬁbroblasts
(Rinn et al., 2008). The pattern of Wnt5a expression overlaps with
Hoxa13 in the UGS (Warot et al., 1997), raising the possibility that
Hoxa13 may interact with Wnt5a during prostatic budding. Furthercharacterization of the regulatory loop between these signaling
molecules may provide clues for how patterning of ventral, as well
as dorsolateral and anterior prostatic budding, is achieved.
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